[Federal Register Volume 64, Number 137 (Monday, July 19, 1999)]
[Notices]
[Page 38685]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-18376]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Glycoprotein Hormone 
Superagonists

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
U.S. Patent Application Serial No. 09/185,408 filed May 6, 1996 
entitled ``Glycoprotein Hormone Superagonists'', to University of 
Maryland, having a place of business in Baltimore, Maryland. The United 
States of America is the assignee of the patent rights in this 
invention.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before 
September 17, 1999 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Charles Maynard, Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 496-7056, ext. 243; Facsimile: (301) 402-0220; e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: This invention relates generally to modified 
glycoprotein hormones and specifically to modifications to a human 
glycoprotein, which create superagonist activity. Glycoprotein hormones 
comprise a family of hormones, which are structurally related 
heterodimers consisting of a species common  sub-unit and a 
distinct  sub-unit that confers the biological activity for 
each hormone. However, this invention is not limited to specific 
hormones, specific subjects such as humans as well as non-humans 
mammals, specific amino acids, specific clinical conditions, specific 
analogs, or specific methods.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: July 12, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 99-18376 Filed 7-16-99; 8:45 am]
BILLING CODE 4140-01-M